Genetics history
Landraces, heritage lines and lineages, with evidence labels.
Craft vs industrial cannabis: did legalisation's commercial model hurt quality?
The founder's opinion is that legalisation's commercial model hurt quality: small, careful growers were priced out by large facilities, and product is now grown to a price. The evidence supports parts of that. Wholesale prices fell by roughly 75-80 %, Oregon's flower is at its lowest price since legalisation, Washington lost about a third of its producer businesses from 2017 to 2023, California's licensed canopy is dominated by a few large farms, Canadian excise duty can take 30 % or more of a producer's gross revenue, and regulators have recalled legal product for mould and pesticides. But no data show the grey market was cleaner, and Health Canada's own testing found illegal flower far dirtier than legal flower. Craft vs industrial is the real fault line. Growing your own, where legal, is the surest way to control quality.
How hybrid 'strains' emerged
Modern drug-type cannabis is mostly a mix of South Asian-derived long-flowering types and Central Asian (Afghan) hashish types, crossed from the 1970s onwards in North America, then distributed by Dutch seed companies from the mid-1980s, and multiplied into thousands of names in clone-driven and legal markets since the 1990s. The broad story is supported by genetics; most specific pedigrees are oral claims with conflicting versions.
Indica, sativa and ruderalis: what the names really mean
Cannabis is one species, Cannabis sativa L., showing different phenotypes. Nearly everything grown today is a hybrid, with a few outlier landraces. Distinct groups, ruderalis included, may have existed long ago, but not today. As a guide to effects or species, indica vs sativa is nonsense: genetic and chemical studies show the labels don't match ancestry or predict chemistry. At most they describe plant shape: leaflet width, structure and flowering time.
Landrace hunting or biopiracy? Benefit-sharing, consent and cannabis
International law says a country owns rights over its genetic resources: under the Convention on Biological Diversity (1992) and the Nagoya Protocol (in force 2014), anyone taking plant material for breeding or research needs prior informed consent and mutually agreed terms, including benefit-sharing. Cannabis falls through the cracks: it isn't in the Plant Treaty's crop list, it's still a Schedule I drug under the 1961 Single Convention, most seed was collected before these rules existed, and the US and Canada aren't Nagoya parties. Turmeric, neem, hoodia and rooibos show what credit and compensation look like when they're taken seriously. GenetixBay's position: credit the source region and community on every record, document provenance honestly with evidence levels, encourage benefit-sharing and fair practice, and reward returning value to source communities.
Landraces of the world: an overview
Drug-type cannabis landraces developed across South and Central Asia and were carried to Africa, the Middle East and the Americas, where local farmers adapted them over centuries. Genomic work points to an Asian origin of domestication (exact region contested). Many traditional landraces are now endangered by hybrid replacement, and most 'landrace' seed in commerce is better described as heirloom: collected at some point, then maintained elsewhere. Every origin story here is a claim; this article labels the evidence.
Old cannabis wasn't weak: the "so much stronger than 20 years ago" myth
"Cannabis is far stronger than it used to be" is false as a claim about the plant's genetics. Famous hashish, charas and sinsemilla traditions are centuries old and impossible with 5 % plants, and old seed grown well today still tests high. The 'weak old weed' numbers come from seized samples: mostly cheap compressed export brick of leaf, seed and stem, often stored for years before testing, measured with changing methods. The best of what source regions grew was rarely exported. What changed is the market and growing technique: fresh, seedless, indoor flower.
Patents and the gene pool: who can own a cannabis plant?
Cannabis can be protected by US utility patents (covering plants, traits, extracts and methods), plant patents (for asexually reproduced varieties) and plant variety protection certificates (for seed-propagated hemp, since 2019), plus plant breeders' rights in Canada and the EU. Grants are public record. Legal commentators worry that thin prior art and broad claims could fence off parts of a shared gene pool. The open responses are public, dated documentation: prior-art databases, open-source seed pledges and genotype registries. GenetixBay's answer is preservation, GB-ID documentation and open sharing.
Same cut, a thousand names: renaming, relabelling and the shrinking gene pool
Renaming clones, relabelling cuts and reusing famous names make the market look far more diverse than it is. Genetic studies find the same plant sold under different names and different plants sold under one name: in one study 35 % of comparisons put a sample closer to a differently named sample than to its namesakes, and in Nevada 637 recorded names (396 after cleaning) covered three chemical profiles. Hidden sameness makes breeders cross near-identical material while believing they're adding diversity. GenetixBay's answer is the GB-ID: a permanent record tied to the plant, its source and its evidence, not to its name.
Why everything tastes the same: the evidence that commercial cannabis is converging
Growers keep saying modern weed all tastes the same, and the data back them up. A study of nearly 90,000 US lab results found THC-dominant flower falling into just three terpene groups, two of which held about 87 % of samples. Strain names and indica/sativa labels promise far more variety than the chemistry shows, traditional landraces in their home regions are being replaced by introduced hybrids, and retail prices rise with THC rather than aroma. GenetixBay's answer is preservation, documentation with GB-IDs, and open sharing of distinctive lines.
Why strain names are unreliable: what genetic studies show
Several genetic and chemical studies of retail cannabis show that the same strain name often hides different genotypes, that 'indica' and 'sativa' labels don't match genome-wide ancestry, and that potency labels vary by lab. Some names are reasonably consistent, many are not. A name is a claim; a documented source, a GB-ID with evidence and, ultimately, DNA are the evidence.
